Slide 1: NYSE American: IGC
NYSE American: IGC 2 August 2023
Slide 2: Safe Harbor
SAFE HARBOR The matters discussed in this presentation include forward-looking statements about the business prospects of IGC Pharma, Inc. Forward-looking statements are often preceded by words such as believes, expects, anticipates, plans, will, goal, may, intends, assumes, or similar expressions.
Slide 3: NYSE American: IGC company snapshot
NYSE American: IGC Avg. Volume (m): 165,000 (as of: 08/02/ 2023) Market Cap ($): 19M (as of: 08/02/ 2023) Stock Price($): 0.35 as of: 08/02/ 2023) Headquarters: Potomac, Maryland, US Industry: Pharmaceutical Full Time Employees: 60 Source: NYSE American: IGC
Slide 4: What is Alzheimer's Disease?
WHAT IS ALZHEIMER’S DISEASE? NYSE American: IGC
Slide 5: Alzheimer's Disease (AD)
Alzheimer’s Disease (AD): AD is a neurodegenerative disease that causes progressive cognitive decline, and neuropsychiatric and behavioral impairment: It is the most common cause of dementia. Its progression is often gradual and difficult to detect. Symptoms arise only years after its onset. It is u
Slide 6: Alzheimer's prevalence and cost
ALZHEIMER’S DISEASE 1 in 9 13.8 Million 65+ yrs. Americans with Americans with Alzheimer’s in 2023 Alzheimer’s by 2050 6.7 million $1 Trillion Americans with Expected total expenses Alzheimer’s age (65+) in for Alzheimer’s and other dementias by 2050 2023 Alzheimer’s Association 2023 Alzheimer’s Dis
Slide 7: Alzheimer's Neurobiology
Alzheimer’s Neurobiology HALLMARKS OF ALZHEIMER'S • Extracellular Plaque: β-amyloid (Aβ) • Tangles: Tau Neurofibrillary Tangles (NTFs) These cause loss of neurons & critical neuronal connections Also linked to Alzheimer's: • Metabolic disruption • Mitochondrial dysfunction • Neuroinflammation Source
Slide 8: Alzheimer's Symptoms
Alzheimer’s Symptoms Behavioral or Neuropsychiatric Symptoms (NPS) • Agitation. • Depression • Apathy • Anxiety • Psychosis. Cognitive Impairment • Loss of memory • Speech • Visuospatial processing, and/or executive function. Non-Neuropsychiatric Symptoms • Including sleep disorders • Weight loss •
Slide 9: Alzheimer's Symptom Progression
Alzheimer’s Symptom Progression Mild Moderate Severe Difficulty navigating familiar areas Leaving stove on Misplacing items Difficulty preparing meals Symptoms Cognitive Forgetting appointments Trouble with simple calculations Consistent apraxia Forgetting bills/medications Difficulty with simple ho
Slide 10: Our Potential Solution
Our Potential Solution The Promise of IGC-AD1 • A natural patent-protected compound in Phase 2B trials that targets neuropsychiatric symptoms such as agitation in Alzheimer’s. • Also, the FIRST compound that relies on low doses of THC a cannabinoid, and another compound as active pharmaceutical agen
Slide 11: First Mover Advantage with Intellectual Property
FIRST MOVER ADVANTAGE WITH INTELLECTUAL PROPERTY Foreign- Patents US-patent Target Description Filed Granted Patent Granted Alzheimer's Disease- IGC-AD1 Use of cannabis-based formulations for treating Central Nervous disorder 10 2 - Alzheimer's Disease- TGR-63 Manufactured molecule with ability to i
Slide 12: Vertically Integrated Operations
VERTICALLY INTEGRATED OPERATIONS Potomac, MD. Vancouver, WA Colombia India . . NYSE American: IGC
Slide 13: IGC-AD1 History/Strategy
IGC-AD1 A PROMISING PATH-BREAKING FORMULATION • At University of South Florida (USF) Professor Cao, discovered the potential of combination therapy with low doses of THC plus IGC-AD1 other molecules to treat Alzheimer’s History/Strategy • Featured on Dr. Sanjay Gupta’s CNN show “Weed 2”. • In 2017,
Slide 14: Pre-Clinical Results on AD Cell Lines
PRE-CLINICAL RESULTS ON AD CELL LINES Decreased plaques and decreased pTau: • Inhibits the aggregation of amyloid plaque • Reduces phosphorylated tau (pTau) • Enhances mitochondrial function • Non-toxic. Repeated low dosing over 48 hours is non- toxic J. Pineal. Res. 2011, 51, 75-86; J. Alzheimer’s
Slide 15: Memory Improved in AD (APP/PS1) Mouse Model
MEMORY IMPROVED IN AD (APP/PS1) MOUSE MODEL AD model mice dosed with the active agent in IGC-AD1 had significantly improved times and less errors in a Morris Water Maze test than those in the control group • The maze uses spatial cues for mice to navigate a swimming container full of stained water a
Slide 16: IGC-AD1 Phase I Trial Completed
IGC-AD1 PHASE I Safety, Tolerability, Agitation, NPS TRIAL COMPLETED No life-threatening or serious adverse Multiple Ascending Dose (MAD) study to evaluate safety and events at any dosing level tolerability of IGC-AD1 in participants with AD & NPS (Neuropsychiatric Symptoms) using the NPI (Neuropsyc
Slide 17: Results on NPS: Average Total NPI
Results on NPS: Neuropsychiatric Symptoms Measured by NPI Scores Total NPI 35,0 ** 31,5 30,0 Results on NPS: 25,0 ** 22,2 Neuropsychiatric Symptoms Measured by Average Total NPI 20,0 Baseline NPI Scores ** 16,0 14,8 * Day 15 15,0 12,4 Patients taking IGC-AD1 intervention 10,0 * showed an overall imp
Slide 18: Agitation Results
Agitation Results NPI Agitation 5,0 4,7 4,5 4,3 4,2 4,0 3,5 3,0 3,0 At three different doses, agitation Average NPI 2,5 Baseline improved both clinically and Day 15 statistically (p <.05) 2,0 1,5 1,4 1,5 1,0 0,5 0,0 Cohort 1 Cohort 2 Cohort 3 NYSEIGC-AD1 American: IGC
Slide 19: Caregiver Testimonials
Caregiver Testimonials From our Phase 1 study “I want to tell you a story that brought incredible joy to me. We participated in your Phase 1 Clinical trial in Puerto “I am a caregiver of my mother, Rico. After about a week of who is 79 years old and suffers medication, one day I came home to from th
Slide 20: Agitation in Alzheimer's Is...
AGITATION IN ALZHEIMER’S IS… Agitation: Physical and verbal aggression, cursing, shouting, crying, repetitive movements. Currently, there are no FDA-approved medications to alleviate agitation in AD dementia 76% of Alzheimer’s patients suffer from agitation Agitation is associated with: • Higher adm
Slide 21: Ongoing IGC-AD1 Phase II Trial
ON GOING IGC-AD1 PHASE II TRIAL Placebo Controlled, Double Blind, Randomized, Multi Site Phase II protocol seeks to show that IGC’s low dose THC based investigational drug, IGC-AD1, is effective, compared to placebo, in lowering agitation in participants with Alzheimer’s Objective • Evaluate if IGC-
Slide 22: TGR-63 Background
TGR-63 A PROMISING PATH-BREAKING MOLECULE • India-based Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) created the TGR-63 molecule. • IGC acquired exclusive rights to TGR-63 from JNCASR researchers in AD DRUG CANDIDATE 2 2022. • Pre-clinical testing demonstrates that TGR-63 holds
Slide 23: Our Drug Candidates Targeting AD
OUR DRUG CANDIDATES TARGETING AD TGR-63 Treatment of Disease A plaque aggregation inhibitor shown in pre-clinical trials to reduce neurotoxicity in AD cell lines and improve memory in AD mouse models. IGC-AD1 Treatment of Symptoms Our lead drug candidate has entered Phase 2 trials for treating agita
Slide 24: Senior Scientific Trial Team
SENIOR SCIENTIFIC TRIAL TEAM Dr. Varduhi Ghazaryan, MD, MPH Medical Director Dr. Saadia Shahnawaz, MD Medical Director Dr. Juan Manuel Orjuela, MD Scientific Neuropsychiatrist Management Jagadeesh Rao, PhD Principal Scientist Diego Rodriguez, PhD Senior Clinical Researcher Evelyn Gutiérrez, Chem Eng
Slide 25: Senior Scientific Trial Team: Inventors and Advisors
SENIOR SCIENTIFIC TRIAL TEAM Prof. Chuanhai Cao, PhD Professor of Pharmaceutical Science Inventors Prof. T Govindaraju, PhD, FRSC. Professor - Bioorganic Chemistry Dr. L. Elliot Hong, MD Professor Psychiatrist Dr. Krista Lanctôt, PhD Professor & Director of Scientific Neuropsychopharmacology Advi
Slide 26: Board of Directors
Board of Directors din Richard John Jim Ram Claudia Prins Lynch Moran Mukunda Grimaldi Chairman Director In memoriam Director CEO VP, CFO, CCO © 5) © a) 5) (€IGCPHARMA NYSE American: IGC
Slide 27: OTC Wellness Products
FOCUS AREA #2 OTC Wellness Products Branded and White label Focused on women NYSE American: IGC
Slide 28: IGC Pharma wellness product line
Find freedom in your period Rest up + recharge Experience quick recovery Heal the whole you '‘<IGCPHARMA NYSE American: IGC
Slide 29: Women's Health & Wellness Science
WOMEN’S HEALTH & WELLNESS SCIENCE • Non-GMO, vegan line of over-the-counter “OTC” wellness products with natural ingredients designed for women by women. • PMS, period cramps, fitness, & sleep, Holief™ covers a spectrum of wellness through a line of products that meets the highest standards and valu
Slide 30: GMP Manufacturing Facilities
GMP Manufacturing Facilities Located at: Vancouver, WA, US. NYSE American: IGC
Slide 31: From Lab-to-Market Sales Beginning to Ramp
FROM LAB-TO-MARKET SALES BEGINNING TO RAMP Unique End-to-end Capabilities FYE 03/31/23 • Our formulations • R&D: Ability to source and manufacture product at scale • Brand creation, fulfillment & shipping • E-commerce and data analytics FYE 03/31/22 • Global customer engagement through strategic par
Slide 32: Diverse Growth Opportunities
DIVERSE GROWTH OPPORTUNITIES Two Patent-protected investigational drug candidates targeting Alzheimer's, IGC-AD1 & TGR-63 IGC-AD1 is currently in Phase 2B. TGR-63 is in tox studies OTC products targeting women's wellness generating revenue now Vertically integrated operations Clean capital structure
Slide 33: Potential to Drive Significant Value
POTENTIAL TO DRIVE SIGNIFICANT VALUE NORTH AMERICA AND EUROPE Individuals with AD 15M 15M 15M Agitation in AD 11M 11M 11M % adoption of drug (IGC- 3% 5% 10% AD1) Annual Price/Patient of drug $1,200 – $2,400 $1,200 – $2,400 $1,200 – $2,400 Estimated Revenue $0.4B – $0.8B $0.8B - $1.3B $1.3B - $2.6B K
Slide 34: Estimated Public Company Valuations During Trials
ESTIMATED PUBLIC COMPANY VALUATIONS DURING TRIALS • Public in CNS. • Year shows year when the company was in the Clinical Stage that is mentioned. Assumptions • Estimated valuation is the valuation at the time the company was closest to Phase entered the Phase that is mentioned. • Current Market val
Slide 35: Action Items
ACTION ITEMS Investor & Public Relations Initiatives Presentations at Conferences, non-deal road shows Communicate trials for additional Alzheimer’s Drugs in the pipeline Complete IGC-AD1 Phase II Trial by end of Q1 2024 Journal Publications Ramp consumer products to provide non-dilutive funding NYS
Slide 36: Thank You
THANK YOU NYSE American: IGC 2 August 2023